APE1 Stock Chart & Stats
€3.10
-€0.24(-4.82%)
At close: 4:00 PM EDT
€3.10
-€0.24(-4.82%)
Day’s Range― - ―
52-Week Range€2.76 - €8.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.95M
Enterprise Value€5.18
Total Cash (Recent Filing)€937.50K
Total Debt (Recent Filing)€102.27K
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.97
Shares Outstanding1,822,121
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.20
Price to Sales (P/S)191.02
P/FCF Ratio-2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.1
Revenue Forecast (FY)€1.52M
Bulls Say, Bears Say
Bulls Say
Strong Preclinical GABAB PipelineRobust efficacy across multiple species, combined with a wide preclinical safety margin and no observed tolerance, supports the potential differentiation of Addex’s GABAB program. If translated clinically, these characteristics could improve partnering interest and create a durable development asset.
Partnered Milestone And Royalty PotentialThe Indivior partnership provides external development support while preserving meaningful milestone and royalty participation. A selected compound that has completed IND-enabling work gives the program a clearer path toward value creation without requiring Addex to fund every development stage internally.
Conservatively Leveraged Balance SheetVery low leverage limits the burden of interest and debt repayment while preserving flexibility for partnerships, asset monetization, or future financing. Although the company remains loss-making, the absence of meaningful debt reduces one important source of financial stress during development.
Bears Say
Persistent Cash BurnContinued negative operating and free cash flow means Addex must rely on financing, partnering, or other asset-related sources to sustain research activities. Until cash generation improves, funding needs can constrain development pace and reduce management’s flexibility in allocating capital.
Tight Short-term LiquidityThe large gap between current assets and current liabilities, alongside a substantial quarterly cash decline, indicates limited near-term liquidity protection. This leaves Addex vulnerable to financing timing and makes continued operations and planned investment dependent on securing additional resources.
Program Progress Depends On FundingKey pipeline opportunities, including the GABAB cough program and dipraglurant development, cannot advance on the current funding base. External financing or partnerships therefore determine the timing of important value-creating milestones and may force unfavorable capital or asset decisions.
Addex Therapeutics News
APE1 FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was €2.76 and its highest was €8.50 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is €2.95M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Nov 09, 2026 which is in 55 days.
How were Addex Therapeutics’s earnings last quarter?
Addex Therapeutics released its earnings results on Jun 25, 2026. The company reported -€0.009 earnings per share for the quarter.
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Overvalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 1,822,121 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Addex Therapeutics reported an EPS of -€0.009 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in DE:APE1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
APE1 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents meaningful scientific and preclinical progress — notably strong antitussive data for the GABAB PAM (Compound A), clear rationale and readiness for dipraglurant in post-stroke/TBI recovery, a value-creating Neurosterix spinout nearing Phase 1 readout, and a partnered program with material milestone upside via Indivior. However, these operational and pipeline positives are tempered by a constrained cash position, increasing reported losses driven by the equity-method share of Neurosterix, and the explicit need for additional financing or partnering to start IND-enabling studies and advance unpartnered programs. Overall, the company shows strong R&D momentum but meaningful near-term financing risk.View all DE:APE1 earnings summariesTechnical Analysis
Kiora Pharmaceuticals
―
Xenetic Biosciences
―
Nucana
―
Creative Medical Technology Holdings
―
HCW Biologics
―